Oramed Pharmaceuticals Inc.
ORMP
$2.33
$0.031.30%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | 0.00 |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | 0.00 |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | 0.00 |
| SG&A Expenses | 2.13M | 847.00K | 1.69M | 1.78M | 2.11M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.60M | 3.09M | 3.14M | 2.96M | 3.88M |
| Operating Income | -3.60M | -3.09M | -3.14M | -2.96M | -3.88M |
| Income Before Tax | -9.78M | -18.51M | 10.84M | 1.53M | 13.30M |
| Income Tax Expenses | 416.00K | 1.13M | 1.63M | -- | -- |
| Earnings from Continuing Operations | -10.20M | -19.64M | 9.20M | 1.53M | 13.30M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 10.00K | 23.00K | 8.00K | 2.00K | 40.00K |
| Net Income | -10.19M | -19.62M | 9.21M | 1.54M | 13.34M |
| EBIT | -3.60M | -3.09M | -3.14M | -2.96M | -3.88M |
| EBITDA | -3.56M | -3.04M | -3.08M | -2.91M | -3.82M |
| EPS Basic | -0.25 | -0.48 | 0.22 | 0.04 | 0.33 |
| Normalized Basic EPS | -0.04 | -0.28 | 0.17 | -0.03 | -0.05 |
| EPS Diluted | -0.26 | -0.48 | 0.22 | 0.04 | 0.32 |
| Normalized Diluted EPS | -0.04 | -0.28 | 0.16 | -0.03 | -0.05 |
| Average Basic Shares Outstanding | 40.67M | 40.90M | 40.96M | 40.84M | 40.52M |
| Average Diluted Shares Outstanding | 40.67M | 40.90M | 41.59M | 41.56M | 41.53M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |